Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium.
Jorik H AmeszSanne J J LangmuurNina EpskampAd J J C BogersNatasja M S de GrootOlivier C ManintveldYannick J H J TavernePublished in: Cardiovascular drugs and therapy (2023)
The addition of empagliflozin to LMS from end-stage heart failure patients cultured in a biomimetic system improves contraction and relaxation kinetics by increasing total contraction duration without diminishing maximum force production. Therefore, we present convincing evidence that SGLT2i can directly act on the myocardium in absence of systemic influences from other organ systems.
Keyphrases
- endothelial cells
- heart failure
- single molecule
- smooth muscle
- liver failure
- drug induced
- respiratory failure
- induced pluripotent stem cells
- ejection fraction
- pluripotent stem cells
- left ventricular
- atrial fibrillation
- acute heart failure
- cardiac resynchronization therapy
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome